After its depression candidate failed a phase 3 trial and disappointed analysts, Neumora is shaking up its leadership team.
Patients with progressive pulmonary fibrosis who received nerandomilast showed improved forced vital capacity from baseline ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback